associated with an increased incidence of rhinoconjunctivitis and eczema. The authors acknowledged that their findings might have been due to confounding ,
antagonist that blocks only the action of ETA, has been approved for use in Canada, Australia, and the European Union, to be marketed under the name ,
トップ   新規 一覧 単語検索 最終更新   ヘルプ   最終更新のRSS